My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece
   Program
   Organisers
   Abstracts
   Participants

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland

Printable version

 

Tuesday June 2

 

 14:00-18:30 Registration
       
 19:30 Welcome reception
       

 

Wednesday June 3

 

08:00-09:00 Registration
       
09:00-09:15 Welcome and Introduction
       
09:15-10:45 Targeting Ebola

Chair: Steven Kern

09:15-09:30 Steven Kern Conducting clinical trials in challenging environments
09:30-09:55 France Mentré Estimating an effective dose for a repurposed drug to treat Ebola: the case of favipiravir
09:55-10:20 Matthias Machacek Estimating an effective dose for a new drug to treat Ebola with incomplete information: the case of Zmapp
10:20-10:45 Scott Berry An Adaptive Platform Trial for Ebola: Application to Future Epidemics
       
10:45-12:15 Coffee break, Poster and Software session I
  Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter
       
12:15-12:55 Diabetes

Chair: IñakiTrocóniz 

12:15-12:35 Roberto Bizzotto A model of glucose clearance to improve the description of glucose homeostasis
12:35-12:55 Rada Savic A longitudinal HbA1c model elucidates genes linked to disease progression on metformin therapy
       
12:55-14:25 Lunch
       
14:25-15:15 On the 20th anniversary of 'Nonlinear models for repeated measurement data'

Chair: France Mentré 

14:25-14:50 David Giltinan Why write a book in 1995 on nonlinear mixed effects modeling?
14:50-15:15 Marie Davidian Subsequent developments in nonlinear mixed effects modeling (link to the video of the presentation)
       
15:15-16:40 Tea break, Poster and Software session II
  Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter
       
16:40-17:40 Other diseases

Chair: Ana Ruiz 

16:40-17:00 José David Gómez-Mantilla Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach
17:00-17:20 Gopichand Gottipati Modeling of a composite score in Parkinson’s disease using item response theory
17:20-17:40 Emilie Hénin Determination of effective blood concentrations of cyclosporine in pediatric severe aplastic anemia based on a time-to-response model
       

 

Thursday June 4

 

09:00-10:20 Lewis Sheiner Student Session

Chair: Rada Savic, Steven Kern and Michael Looby

09:00-09:25 Huixin Yu Development of a tumour growth inhibition model to elucidate the effect of ritonavir on intratumoural metabolism and anti-tumour effect of docetaxel in a mouse model for hereditary breast cancer
09:25-09:50 Shan Pan Automated proper lumping for simplification of systems models
09:50-10:15 Adrien Tessier Modelling pharmacogenetic data in population studies during drug development
10.15-10.20 Presentation of Lewis Sheiner student session awards
       
10:20-11:45 Coffee break, Poster and Software session III
  Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter
       
11:45-12:50 Applied Bayesian Inference for Pharmacometrics

Chair: Paolo Magni 

11:45-12:05 Michael Betancourt Part I: Building Robust PK/PD Population Models with Bayesian Inference
12:05-12:30 Sebastian Weber Part II: Building Robust PK/PD Population Models with Bayesian Inference
12:30-12:50 Thierry Wendling Application of a Bayesian population approach to physiologically-based modelling and simulation of mavoglurant pharmacokinetics
       
12:50-14:10 Lunch
       
14:10-15:10 PKPD and drug resistance in infectious diseases

Chair: Oscar Della Pasqua and Jonathan Mochel 

14:10-14:30 Rong Deng Towards Model-Based Drug Development of New Therapeutics for Hepatitis C Virus
14:30-14:50 Joe Standing Treating resistant Gram-negatives: bedside to bench and back
14:50-15:10 Anders Kristoffersson A PKPD model characterizing resistance for predictions of bacterial kill in vivo
       
15:10-15:15 Announcement of WCoP 2016

Nick Holford 

       
15:15-16:30 Tea break, Poster and Software session IV
  Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter
       
16:30-17:30 Stuart Beal Methodology Session

Chair: Pascal Girard 

16:30-16:50 Andrew Hooker Preconditioning of nonlinear mixed effect models for stabilization of the covariance matrix computation
16:50-17:10 Eric Strömberg Simulated model based adaptive optimal design of adult to children bridging study using FDA stopping criteria
17:10-17:30 Sebastian Ueckert Alternative to resampling methods in maximum likelihood estimation for NLMEMs by borrowing from Bayesian methodology
       

 

Friday June 5

 

09:15-10:15 Infectious diseases

Chair: Marylore Chenel

09:15-09:35 Joel Tarning Semi-mechanistic time-to-event modelling in malaria
09:35-09:55 Natalie Filmann Modeling the PK/PD of hepatitis B immunoglobulin after hepatitis B induced liver transplantation by an extended target mediated drug disposition model
09:55-10:15 Dimitra Bon Multiscale modelling for hepatitis C treatment
       
10.15-10.25 Preview of PAGE 2016
       
10:25-10:55 Coffee break and Software session
       
10:55-12:15 Modelling in oncology

Chair: Dinesh De Alwis

10:55-11:15 Nadia Terranova Analysis of individual target lesions for tumor size models of drug resistance: a new methodology encompassing signal processing and machine learning
11:15-11:35 Nelleke Snelder PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin – What is the optimal testosterone level?
11:35-11:55 Anna Georgieva Kondic Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison
11:55-12:15 Pauline Mazzocco Modeling the emergence of resistance in low-grade glioma patients treated with temozolomide, and simulations using a stochastic approach
       
12.15-12.25 Closing remarks
       
12:25-12:45 Audience Input for the PAGE 2016 Program